RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $462

Benzinga Newsdesk www.benzinga.com Positive 93.5%

Neg 0% Neu 0% Pos 93.5%

RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $449 to $462.